|
[1]European Association for the Study of the Liver.EASL clinical practice guidelines:management of chronic hepatitis B virus infection[J].J Hepatol,2012,57(1):167-185.
|
|
[2]LIAW YF,KAO JH,PIRATVISUTH T,et al.Asian-Pacific consensus statement on the management of chronic hepatitis B:a 2012 update[J].Hepatol Int,2012,6(3):531-561.
|
|
[3]LOK AS,McM AHON BJ.Chronic hepatitis B:update 2009[J].Hepatology,2009,50(3):661-662.
|
|
[4] Chinese Society of Hepatology and Chinese Society of Infectious Diseases,Chinese Medical Association.The guideline of prevention and treatment for chronic hepatitis B(2010 version)[J].Clin JHepatol,2011,19(1):13-24.(in Chinese)中华医学会肝病学分会,中华医学会感染病学分会.慢性乙型肝炎防治指南(2010年版)[J].中华肝脏病杂志,2011,19(1):13-24.
|
|
[5]HA M,ZHANG G,DIAO S,et al.A prospective clinical study in hepatitis B e antigen-negative chronic hepatitis B patients with stringent cessation criteria for adefovir[J].Arch Virol,2012,157(2):285-290.
|
|
[6]LIANG Y,JIANG J,SU M,et al.Predictors of relapse in chronic hepatitis B after discontinuation of anti-viral therapy[J].Alment Pharmacol Ther,2011,34(3):344-352.
|
|
[7]CHEN L,LI XL,GAN QR,et al.Clinical characteristics of and factors related to relapse in chronic hepatitis B patients after nucleot(s)ide analogues withdrawal[J].Chin J Hepatol,2013,21(11):825-828.(in Chinese)陈立,李孝楼,甘巧蓉,等.核苷(酸)类似物治疗慢性乙型肝炎停药复发患者的临床特点及其影响因素[J].中华肝脏病杂志,2013,21(11):825-828.
|
|
[8]MAO Q.Current status of antiviral therapy in patients with chronic hepatitis B virus infection and related thoughts[J].J Pract Hepatol,2013,16(4):289-292.(in Chinese)毛青.慢性乙型肝炎病毒感染者抗病毒治疗的现状与思考[J].实用肝脏病杂志,2013,16(4):289-292.
|
|
[9]KWON JH,JANG JW,CHOI JY,et al.Should lamivudine monotherapy be stopped or continued in patients infected with hepatitis B with favorable responses after more than 5 years of treatment?[J].J Med Virol,2013,85(1):34-42.
|
|
[10]CAI W,XIE Q,AN B,et al.On-treatment serum HBsA g level is predictive of sustained off-treatment virologic response to telbivudine in HBeA g-positive chronic hepatitis B patients[J].J Clin Virol,2010,48(1):22-26.
|
|
[11]CHEN CH,LU SN,HUNG CH,et al.The role of hepatitis B surface antigen quantification in predicting HBsA g loss and HBV relapse after discontinuation of lamivudine treatment[J].J Hepatol,2014,61(3):515-522.
|
|
[12]CHEN CH,HUNG CH,HU TH,et al.Association between level of hepatitis B surface antigen and relapse after entecavir therapy for chronic hepatitis B virus infection[J].Clin Gastroenterol Hepatol,2015,13(11):1984-1992.
|
|
[13]LEE HC,SUH DJ,RYU SH,et al.Quantitative polymerase chain reaction assay for serum hepatitis B virus DNA as a predictive factor for post-treatment relapse after lamivudine induced hepatitis B e antigen loss or seroconversion[J].Gut,2003,52(12):1779-1783.
|
|
[14]SONG BC,CUI XJ,CHO YK,et al.New scoring system for predicting relapse after lamivudine-induced hepatitis B e-antigen loss in chronic hepatitis B patients[J].Hepatol Res,2009,39(11):1064-1071.
|
|
[15]JIANG JN,HUANG ZL,HE LX,et al.Residual amount of HBVDNA in serum is related to relapse in chronic hepatitis B patients after cessation of nucleos(t)ide analogs[J].J Clin Gastroenterol,2015,49(4):323-328.
|
|
[16] LOK AS,McM AHON BJ.Chronic hepatitis B[J].Hepatology,2007,45(2):507-539.
|
|
[17]ZHUANG H,WENG XH.Discussion of discontinuation of nucleoside and nucleotide analogs in the treatment of chronic hepatitis B[J].Chin J Viral Dis,2013,3(4):241-244.(in Chinese)庄辉,翁心华.核苷(酸)类似药物治疗慢性乙型肝炎停药的探讨[J].中国病毒病杂志,2013,3(4):241-244.
|
DownLoad: